\begin{table}
	\centering
	\caption{Relative incidence in at-risk period versus control period of all outcomes (modelled independently) for all vaccines, adjusted for season.}
	\label{tab:ri}
	\resizebox{\textwidth}{!}{%
	\begin{tabular}{lrrrrrrrrr}
		\toprule
		& \multicolumn{3}{c}{Zoster vaccine} & \multicolumn{3}{c}{Pneumococcal vaccine} & \multicolumn{3}{c}{Influenza vaccine}\\
		\cmidrule(lr){2-4} \cmidrule(lr){5-7} \cmidrule(lr){8-10}
		& At-risk & Control & & At-risk & Control & & At-risk & Control & \\
		& n (PD) & n (PD) & RI (95\% CI) & n (PD) & n (PD) & RI (95\% CI) & n (PD) & n (PD) & RI (95\% CI)\\
		\midrule 
		Injection site reaction & 37 (833) & 104 (96 876) & 77.4 (48.1, 124.6) & 30 (378) & 138 (102,318) & 65.0 (31.6, 133.6) & 29 (1,071) & 102 (84,934) & 6.62 (3.42, 12.8) \\
		
		Burn & 72 (23,798) & 1,282 (511,166) & 1.23 (0.97, 1.57) & 8 (5,259) & 1,455 (564,087) & 0.55 (0.27, 1.13) & 145 (57,946) & 1,036 (407,960)&0.93 (0.76, 1.14)\\
		
		Myocardial infarction & 12 (8,327) & 436 (221,244) & 0.74 (0.41, 1.33) & 2 (2,729) & 469 (237,376) & 0.39 (0.09,1.59) & 47 (23,226) & 324 (176,808) & 1.17 (0.82, 1.66) \\
		
		Stroke & 50 (35,113) & 1,984 (793,445) & 0.58 (0.44, 0.78) & 15 (9,081)& 2,132 (868,410) & 0.72 (0.42, 1.21) & 197 (88,397) & 1,500 (633,321) & 1.06 (0.89, 1.26)\\
		
		Any rash & 422 (228,311)& 10,381 (4,990,170) & 0.97 (0.88, 1.08) & 115 (52,961) & 11,959 (5,497,005) & 1.01 (0.84, 1.23) & 1,124 (564,634) & 8,645 (3,982,480)& 1.06 (0.98, 1.14) \\
		 
		Rash with antiviral & 61 (33,800) & 1,570 (856,854) & 0.83 (0.62, 1.10) & 22 (10,571) & 1,931 (1,099,845) & 1.23 (0.77, 1.95) & 104 (73,998) & 917 (455,454) & 0.78 (0.62, 0.97) \\
		
		Clinical attendance & 79,352 (3,726,764)& 1,799,288 (79,138,828)& 0.94 (0.94, 0.95)& 19,616 (848,864)& 2,032,393 (87,483,370)& 1.06 (1.04, 1.07)& 200,785 (8,840,389)& 1,368,928 (63,862,675) & 1.03 (1.02, 1.03)\\
		
		\bottomrule
		\multicolumn{10}{l}{RI: relative incidence of at-risk compared to control, PD: person-days.}
	\end{tabular}}
\end{table}